The Effect of GS‐548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS‐6637 in Healthy Adults

Abstract

ANS-6637, a pro-drug of GS-548351, is a selective, reversible inhibitor of aldehyde dehydrogenase isoform 2 under development as an anticraving agent for the treatment of substance use disorders. In vitro testing indicates that GS-548351 is an inhibitor and inducer of cytochrome P450 family 3, subfamily A (CYP3A). In this phase 1 single-center, open-label, fixed-sequence drug-drug interaction study we assessed the impact of steady-state GS-548351 on single-dose pharmacokinetics of midazolam, an index substrate for CYP3A. Twelve healthy volunteers received 600 mg of ANS-6637 by mouth daily from study days 3 to 8 and a single 5-mg oral dose of midazolam on days 1 and 8. Pharmacokinetic samples were collected over 24 hours on days 1 and 8, then analyzed using liquid chromatography-tandem mass spectrometry. The prespecified no-effect range for the 90% confidence interval (CI) of the geometric mean ratio (GMR) of midazolam coadministered with ANS-6637 (day 8) compared with midazolam alone (day 1) was 0.7-1.43. There was an increase in midazolam AUC_0-∞ (GMR [90%CI]) that was within the no-effect range (1.26 [1.12-1.425]) and an increase in midazolam C_max that was outside the range (1.22 [1.03-1.45]). The AUC_0-∞ (1.08 [0.91-1.27]) and C_max (0.95 [0.75-1.2]) of 1-hydroxymidazolam, the primary metabolite of midazolam, were also within the no-effect range. A single grade 3 adverse event (alanine aminotransferase elevation) was identified and resolved following discontinuation of the study drug. Overall, multidose ANS-6637 was well tolerated and did not alter the PK of midazolam beyond a small increase in AUC_0-∞ that is unlikely to be clinically significant.

Related Papers

• → Oral administration of a low dose of midazolam (75�?g) as an in vivo probe for CYP3A activity(2004)95 cited
• Single plasma sampling to predict oral clearance of CYP3A probe midazolam.(2001)
• → Relationship between low midazolam metabolism by cytochrome P450 3A in mice and the high incidence of birth defects(2018)10 cited
• → Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19(1996)2 cited
• → EVALUATING THE SAFETY OF MIDAZOLAM FOR PROCEDURAL SEDATION IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE PATIENTS ON PROTEASE INHIBITORS(2007)1 cited